(EW) Edwards Lifesciences - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 47.155m USD | Total Return: 14.1% in 12m

Heart Valves, Catheters, Surgical Devices, Cardiovascular Care
Total Rating 47
Safety 80
Buy Signal -0.28
Medical Devices
Industry Rotation: -2.9
Market Cap: 47.2B
Avg Turnover: 356M USD
ATR: 2.76%
Peers RS (IBD): 56.5
Risk 5d forecast
Volatility27.0%
Rel. Tail Risk-14.2%
Reward TTM
Sharpe Ratio0.40
Alpha-5.38
Character TTM
Beta0.504
Beta Downside0.577
Drawdowns 3y
Max DD37.53%
CAGR/Max DD-0.07
EPS (Earnings per Share) EPS (Earnings per Share) of EW over the last years for every Quarter: "2021-03": 0.54, "2021-06": 0.64, "2021-09": 0.54, "2021-12": 0.51, "2022-03": 0.6, "2022-06": 0.63, "2022-09": 0.61, "2022-12": 0.64, "2023-03": 0.62, "2023-06": 0.66, "2023-09": 0.59, "2023-12": 0.64, "2024-03": 0.66, "2024-06": 0.7, "2024-09": 0.67, "2024-12": 0.59, "2025-03": 0.64, "2025-06": 0.67, "2025-09": 0.67, "2025-12": 0.58, "2026-03": 0,
EPS CAGR: -47.04%
EPS Trend: -39.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of EW over the last years for every Quarter: 2021-03: 1216.6, 2021-06: 1376, 2021-09: 1310.2, 2021-12: 1329.7, 2022-03: 1341.2, 2022-06: 1373.9, 2022-09: 1319, 2022-12: 1348.3, 2023-03: 1459.6, 2023-06: 1295.5, 2023-09: 1243.4, 2023-12: 1266.4, 2024-03: 1329.9, 2024-06: 1385.9, 2024-09: 1354.4, 2024-12: 1385.8, 2025-03: 1412.7, 2025-06: 1532.2, 2025-09: 1553.1, 2025-12: 1569.6, 2026-03: null,
Rev. CAGR: 4.28%
Rev. Trend: 62.8%
Last SUE: 0.18
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: EW Edwards Lifesciences

Edwards Lifesciences Corporation (EW) develops products for advanced cardiovascular diseases globally. The company specializes in transcatheter and surgical heart valve therapies. This includes transcatheter aortic valve replacement (TAVR) systems, a key growth area in medical devices, and products for mitral and tricuspid valve diseases.

Their product portfolio features the Edwards SAPIEN family for TAVR, PASCAL and EVOQUE for valve repair/replacement, and INSPIRIS and KONECT RESILIA for surgical applications. The medical device sector is characterized by high R&D investment and regulatory hurdles. Products are distributed via direct sales and independent distributors.

Further analysis on ValueRay can provide deeper insights into EWs market position and financial performance.

Headlines to Watch Out For
  • SAPIEN valve sales drive transcatheter aortic valve replacement revenue
  • New product launches expand mitral and tricuspid valve market share
  • Regulatory approvals impact market access for innovative devices
  • Healthcare spending trends influence demand for cardiovascular procedures
Piotroski VR‑10 (Strict) 7.5
Net Income: 1.07b TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.45 > 1.0
NWC/Revenue: 81.17% < 20% (prev 87.61%; Δ -6.44% < -1%)
CFO/TA 0.12 > 3% & CFO 1.60b > Net Income 1.07b
Net Debt (-3.52b) to EBITDA (1.39b): -2.53 < 3
Current Ratio: 3.72 > 1.5 & < 3
Outstanding Shares: last quarter (581.8m) vs 12m ago -1.47% < -2%
Gross Margin: 78.08% > 18% (prev 0.79%; Δ 7.73k% > 0.5%)
Asset Turnover: 45.36% > 50% (prev 41.79%; Δ 3.57% > 0%)
Interest Coverage Ratio: 60.53 > 6 (EBITDA TTM 1.39b / Interest Expense TTM 20.4m)
Altman Z'' 10.00
A: 0.36 (Total Current Assets 6.74b - Total Current Liabilities 1.81b) / Total Assets 13.70b
B: 1.04 (Retained Earnings 14.24b / Total Assets 13.70b)
C: 0.09 (EBIT TTM 1.23b / Avg Total Assets 13.38b)
D: 4.36 (Book Value of Equity 14.66b / Total Liabilities 3.36b)
Altman-Z'' Score: 10.95 = AAA
Beneish M -2.89
DSRI: 1.13 (Receivables 912.1m/727.4m, Revenue 6.07b/5.46b)
GMI: 1.01 (GM 78.08% / 79.07%)
AQI: 0.96 (AQ_t 0.37 / AQ_t-1 0.38)
SGI: 1.11 (Revenue 6.07b / 5.46b)
TATA: -0.04 (NI 1.07b - CFO 1.60b) / TA 13.70b)
Beneish M-Score: -2.89 (Cap -4..+1) = A
What is the price of EW shares? As of April 11, 2026, the stock is trading at USD 77.87 with a total of 3,854,127 shares traded.
Over the past week, the price has changed by -4.09%, over one month by -9.22%, over three months by -6.19% and over the past year by +14.08%.
Is EW a buy, sell or hold? Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.
  • StrongBuy: 10
  • Buy: 4
  • Hold: 17
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the EW price?
Analysts Target Price 96.9 24.5%
Edwards Lifesciences (EW) - Fundamental Data Overview as of 07 April 2026
P/E Trailing = 44.8564
P/E Forward = 27.3224
P/S = 7.7716
P/B = 4.5203
P/EG = 2.0832
Revenue TTM = 6.07b USD
EBIT TTM = 1.23b USD
EBITDA TTM = 1.39b USD
Long Term Debt = 598.3m USD (from longTermDebt, last quarter)
Short Term Debt = 24.5m USD (from shortTermDebt, last quarter)
Debt = 705.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.52b USD (recalculated: Debt 705.4m - CCE 4.23b)
Enterprise Value = 43.63b USD (47.16b + Debt 705.4m - CCE 4.23b)
Interest Coverage Ratio = 60.53 (Ebit TTM 1.23b / Interest Expense TTM 20.4m)
EV/FCF = 32.68x (Enterprise Value 43.63b / FCF TTM 1.33b)
FCF Yield = 3.06% (FCF TTM 1.33b / Enterprise Value 43.63b)
FCF Margin = 22.00% (FCF TTM 1.33b / Revenue TTM 6.07b)
Net Margin = 17.64% (Net Income TTM 1.07b / Revenue TTM 6.07b)
Gross Margin = 78.08% ((Revenue TTM 6.07b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 78.30% (prev 77.77%)
Tobins Q-Ratio = 3.19 (Enterprise Value 43.63b / Total Assets 13.70b)
Interest Expense / Debt = 2.89% (Interest Expense 20.4m / Debt 705.4m)
Taxrate = 28.98% (26.2m / 90.4m)
NOPAT = 876.9m (EBIT 1.23b * (1 - 28.98%))
Current Ratio = 3.72 (Total Current Assets 6.74b / Total Current Liabilities 1.81b)
Debt / Equity = 0.07 (Debt 705.4m / totalStockholderEquity, last quarter 10.34b)
Debt / EBITDA = -2.53 (Net Debt -3.52b / EBITDA 1.39b)
Debt / FCF = -2.64 (Net Debt -3.52b / FCF TTM 1.33b)
Total Stockholder Equity = 10.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.0% (Net Income 1.07b / Total Assets 13.70b)
RoE = 10.39% (Net Income TTM 1.07b / Total Stockholder Equity 10.30b)
RoCE = 11.33% (EBIT 1.23b / Capital Employed (Equity 10.30b + L.T.Debt 598.3m))
RoIC = 8.04% (NOPAT 876.9m / Invested Capital 10.90b)
WACC = 7.68% (E(47.16b)/V(47.86b) * Re(7.76%) + D(705.4m)/V(47.86b) * Rd(2.89%) * (1-Tc(0.29)))
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -2.09%
[DCF] Terminal Value 76.41% ; FCFF base≈1.08b ; Y1≈874.7m ; Y5≈611.4m
[DCF] Fair Price = 27.23 (EV 12.18b - Net Debt -3.52b = Equity 15.70b / Shares 576.5m; r=7.68% [WACC]; 5y FCF grow -22.61% → 3.0% )
EPS Correlation: -39.41 | EPS CAGR: -47.04% | SUE: -4.0 | # QB: 0
Revenue Correlation: 62.83 | Revenue CAGR: 4.28% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.75 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=+1 | Analysts=23
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=+0.006 | Chg30d=+0.007 | Revisions Net=+1 | Growth EPS=+15.8% | Growth Revenue=+9.9%
EPS next Year (2027-12-31): EPS=3.31 | Chg7d=+0.006 | Chg30d=+0.005 | Revisions Net=+21 | Growth EPS=+11.7% | Growth Revenue=+9.9%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.7% (Discount Rate 7.9% - Earnings Yield 2.2%)
[Growth] Growth Spread = +4.2% (Analyst 9.8% - Implied 5.7%)
External Resources
Dataroma Stockcircle